Bristol-Myers Squibb slips

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083.57 and the Dow Jones Industrial Average DJIA falling 0.28% to 44,747.63.
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down.
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to Chuck Triano,
Bristol-Myers Squibb slips as 2025 outlook disappoints
Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of consensus. Read more here.
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion in costs through 2027. That initiative came after the company began executing a plan to reduce costs by $4 billion.
Bristol Myers Forecasts 2025 Revenue Below Estimates After Strong Quarter
The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the range of $6.55 to $6.85 a share, below the average analyst estimate of $6.92 a share.
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs.
Bristol sees sharper 2025 revenue drop after better-than-forecast Q4
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...
BioSpace14h
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...
Investor's Business Daily on MSN9h
Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook
Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by ...
BioPharma Dive12h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
These Stocks Are Moving the Most Today: Qualcomm, Lilly, Skyworks, Ford, Honeywell, Strategy, Roblox, Bristol Myers, Amazon, and More
Qualcomm trades lower after earnings, Eli Lilly stock rises on upbeat guidance, Skyworks says its share of the business to ...